Latest Global Markets News

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Delegat Group (NZX:DGL) reported a 20% jump in operating NPAT to NZD 61.5 million for FY26, driven by record EBITDA and a 4% rise in global case sales. The Board declared a 22-cent dividend, up 10%, while net debt fell by NZD 51.8 million.

Austco Healthcare has delivered record FY26 financial results, driven by strong organic growth, acquisitions, and a growing software maintenance base, positioning the company for sustained earnings momentum.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.

Advanced Braking Technology Ltd (ASX: ABV) posted a 22.7% revenue increase to $23.48 million and a 16.6% rise in net profit after tax to $2.075 million for FY26, driven by international expansion and advances in autonomous braking technology.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.

Acusensus posted a 45% jump in FY26 revenue to $86.2 million, driven by major contract wins in New Zealand and the US, alongside robust domestic expansions. Despite a widened net loss due to a $16 million litigation settlement, adjusted EBITDA climbed 49%, reflecting operational momentum and strategic investments.

Woodside Energy delivered a strong first half in 2026, with revenue up 13% to $7.45 billion, net profit after tax reaching $1.67 billion, and key LNG and oil projects advancing on schedule. The company declared a fully franked interim dividend of 57 US cents per share amid ongoing global market volatility.

Advanced Engineered Materials (ASX:AEM) reported an 85% jump in high purity alumina sales in 1H 2026, with a customer pipeline now valued at US$190 million amid tightening global supply and rising semiconductor industry demand.